Seeking Alpha

Michael Sweeney's  Instablog

Michael Sweeney
Send Message
Michael Sweeney is an investor in and advocate of Bitcoin. is a bitcoin fund set up to invest in Bitcoin and digital currency opportunities. The fund will NOT have a traditional bank account as investments and distributions are 100% in bitcoin. Current investments and opportunities... More
My company:
  • Vicor Technologies (OTCBB: VCRT) - Breaking down the "PD2i(R) Studies" 1 comment
    Aug 30, 2010 8:44 AM

    Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i® nonlinear algorithm and software.

    Last week, David H. Fater, CEO of Vicor Technologies (OTCBB: VCRT) put out a press release with abstracts from three studies involving its "PD2i® nonlinear algorithm have been accepted for presentation during the Poster Session of the 2010 Heart-Brain Summit".  Vicor is currently in the process of commercializing diagnostics that accurately risk stratify specific target populations for future pathological events including cardiac death resulting from arrhythmia or pump failure, and autonomic nervous system dysfunction, and trauma victims in need of lifesaving intervention.

    Fater stated:

    "We believe the results achieved by the PD2i® in each of these studies suggest the prospect of incorporating the PD2i® nonlinear algorithm into a noninvasive diagnostic that will significantly contribute to the identification and treatment of at-risk patients. We hope that having the opportunity to share these results with those active in the field of heart-brain medicine worldwide will further opportunities to advance study of the PD2i® as a noninvasive diagnostic to identify at-risk populations and further our commercialization efforts for the PD2i®."

    The three studies that will be presented are:

    1. Short-Term Heart Rate Complexity Determined by the PD2i® Algorithm is Reduced in Patients with Type 1 Diabetes Melitus -- The objective of this study was to test the ability of PD2i® to discriminate between young DM patients without neuropathy and age- and gender-matched controls.

    2. Prognostic Significance of PD2i® in Heart Failure Patients -- The goal of this effort was to determine the PD2i®'s ability to predict cardiac events in chronic heart failure patients. The study population was a group of chronic heart failure patients, who had been studied for 44 months, on average, with total mortality as primary endpoint and cardiac mortality, sudden cardiac death, and heart failure death as secondary endpoints.

    3. Mild Hypovolemia and PD2i® -- The goal of this pilot study was to test the ability of the PD2i® to identify acute hypovolemia in blood donors as a preliminary step toward ascertaining whether it could be a useful noninvasive diagnostic for detecting blood loss from internal bleeding. Study subjects were volunteers who presented for a standard single unit whole blood donation. A 15-minute ECG recording was made pre-donation and the recording was then continued during the donation period and a rest afterwards. 

    The Heart-Brain Summit, now in its fifth year, is the annual event of The Society for Heart Brain Medicine. More than 200 physicians, researchers, scientists, and industry professionals from around the world attended the 4th Annual Heart-Brain Summit in 2009.

    The Society for Heart Brain Medicine was officially established as a 501(c) (3) organization in June of 2008, with the purpose of:

    • educating clinicians and scientists about the physiology, pathophysiology, and medical aspects of heart-brain interactions;
    • educating the public about these aspects; and
    • promoting and fostering research into heart-brain relationships.

    The Society for Heart-Brain Medicine provides a forum for researchers and clinicians from different disciplines, both clinical and laboratory, to present, discuss, and evaluate data, and promotes the study of heart-brain medicine as a discipline in its own right. Additional information about the Society for Heart-Brain Medicine is available at

    Dr. James E. Skinner, Vicor Vice President and Director of Grant Research, will present the following abstracts at the 2010 Heart-Brain Summit, which will be held at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, September 23-24. The Poster Session is on September 23, from 5:00 to 7:00pm. This should give Vicor significant exposure in the industry.

    Disclosure: no positionresearch,proactive,vicor,vcrt,aabb,heart failure,scdheft,cardiologist,510k,david fater,pd21,heart brain summit,james skinner,cleveland clinic,2010 heart summit
Back To Michael Sweeney's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (1)
Track new comments
  • deeppocketsgolf
    , contributor
    Comments (114) | Send Message
    VCRT: Vicor Technologies:


    Current Market Cap; 7.06M;


    @ 10 Cents; Per Equity; Accum Deficit (59.708M); Equity (8.428M);
    Development Stage Since 2000;


    Desired Level / Sum Trading At: ,Primary Metric per Equity: ($8.428) M, 1000.013 ,Metric Weighted per Price Range / Change, 6.8_12_404 ,Combined Weight Adj Trade Metric, 1512.106 ,for -($1.7)M Market Cap, for, (0.04) off .14;


    Estimate of Forward Activity:


    Equity Deficit$$MM: (8)
    MinRetGrowth: 0.03
    MinRetInv: 0.05
    Weighted Cost of Capital: 85.904%
    Estimated Local Continuing Value in $$M: (4)
    Estimated Factor NOT LOCAL in $$M: 1.33
    Estimated ContinuingValue : In Line with Development Stage Expenses Since 2000;: (5.436,551)
    Est NOT LOCAL Price / 4.048M Market Cap : 0.08606
    (0.12) ,Factor Forward.
    (0.74) ,Not Local Price To.


    Vicor is a medical diagnostics company focused on commercializing noninvasive diagnostic technology products based on its patented, proprietary point correlation dimension algorithm (the PD2i® Algorithm”).
    The PD2i®Algorithm facilitates the ability of physicians to accurately risk stratify a specific target population to predict future pathological events such as autonomic nervous system dysfunction, cardiac mortality (either from arrhythmic death or congestive heart failure) and imminent death from trauma.
    The Company believes that the PD2i® Algorithm represents a noninvasive monitoring technology that physicians and other members of the medical community can use as a new and accurate vital sign and is currently commercializing two proprietary diagnostic medical products which employ software utilizing the PD2i® Algorithm: the PD2i Analyzertm (sometimes also referred to as the PD2i Cardiac Analyzertm and the PD2i-VStm (Vital Sign). It is also anticipated that the PD2i®Algorithm applications will allow for the early detection of cerebral disorders as well as other disorders and diseases.




    Enter VCRT and Get Info @



    Off the high of 75 Cents;


    Do not own Shares of VCRT; Review the Company;
    5 Jul 2011, 10:06 AM Reply Like
Full index of posts »
Latest Followers


More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.